
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          Adult_NNP human_JJ bone_NN marrow_NN contains_VBZ a_DT minority_NN population_NN
          of_IN MSCs_NNP that_WDT contribute_VBP to_TO the_DT regeneration_NN of_IN tissues_NNS
          such_JJ as_IN bone_NN ,_, cartilage_NN ,_, muscle_NN ,_, ligaments_NNS ,_, tendons_NNS ,_, fat_JJ ,_,
          and_CC stroma_NN ._. Evidence_NN that_IN these_DT MSCs_NNP are_VBP pluripotent_NN ,_,
          rather_RB than_IN being_VBG a_DT mixture_NN of_IN committed_VBN progenitor_NN cells_NNS
          each_DT with_IN a_DT restricted_VBN potential_JJ ,_, includes_VBZ their_PRP$ rapid_JJ
          proliferation_NN in_IN culture_NN ,_, a_DT characteristic_JJ morphology_NN ,_,
          the_DT presence_NN of_IN typical_JJ marker_NN proteins_NNS ,_, and_CC their_PRP$
          consistent_JJ differentiation_NN into_IN various_JJ mesenchymal_NN
          lineages_NNS ._. These_DT attributes_NNS are_VBP maintained_VBN through_IN
          multiple_JJ passages_NNS and_CC are_VBP identifiable_JJ in_IN individual_JJ stem_NN
          cells_NNS ._.
        
        
          Aims_VBZ
          Since_IN stem_NN cells_NNS are_VBP present_JJ in_IN both_DT the_DT bone_NN marrow_NN
          and_CC other_JJ tissues_NNS ,_, we_PRP thought_VBD it_PRP possible_JJ that_IN cells_NNS with_IN
          a_DT similar_JJ appearance_NN and_CC pluripotent_NN mesenchymal_NN
          potential_NN would_MD be_VB present_JJ in_IN the_DT blood_NN ._. We_PRP applied_VBD
          techniques_NNS used_VBN successfully_RB with_IN marrow_NN MSCs_NNP to_TO identify_VB
          similar_JJ cells_NNS in_IN elutriation_NN fractions_NNS of_IN normal_JJ human_JJ
          blood_NN ._.
        
        
          Methods_NNP
          BMPCs_NNP were_VBD elutriated_JJ by_IN diluting_VBG the_DT buffy_NN coats_NNS from_IN
          500_CD ml_NN of_IN anticoagulant-treated_JJ ,_, platelet-depleted_JJ blood_NN
          1_CD :_: 4_CD in_IN RPMI-_NNP 1640_CD medium_NN (_( RPMI_NNP )_) and_CC layering_VBG 25_CD -_: ml_NN
          portions_NNS over_IN 20_CD ml_NN of_IN Lymphoprep_NNP ™_NN ._. These_DT samples_NNS were_VBD
          centrifuged_JJ at_IN 2000_CD rpm_NN for_IN 20_CD min_NN ._. The_DT leukocyte-rich_JJ
          interface_NN cells_NNS were_VBD collected_VBN ,_, made_VBD up_IN to_TO 20_CD ml_NN in_IN RPMI_NNP ,_,
          and_CC separated_VBN by_IN density-gradient_JJ centrifugation_NN ._. The_DT
          interface_NN cells_NNS ,_, now_RB depleted_VBN of_IN red_JJ blood_NN cells_NNS ,_, were_VBD
          collected_VBN ,_, resuspended_JJ in_IN 50_CD ml_NN of_IN sterile_JJ RMPI_NNP and_CC 5_CD %_NN
          heat-inactivated_JJ FCS_NNP ,_, and_CC introduced_VBD into_IN the_DT sample_NN line_NN
          of_IN the_DT flow_NN system_NN of_IN a_DT Beckman_NNP JE-_NNP 50_CD cell_NN elutriator_NN
          charged_VBN with_IN elutriation_NN buffer_NN ._. The_DT chamber_NN was_VBD
          centrifuged_JJ at_IN 25_CD 000_CD rpm_NN at_IN 10_CD °_NN C_NNP and_CC the_DT flow_NN rate_NN
          adjusted_VBN to_TO 12_CD ml_NN /_NN min_NN ._. After_IN about_IN 150_CD ml_NN had_VBD been_VBN
          collected_VBN ,_, the_DT flow_NN rate_NN was_VBD increased_VBN by_IN 1_CD ml_NN /_NN min_NN ._.
          Fractions_NNP nos_NNS ._. 1_LS -_: 6_CD (_( flow_NN rates_NNS of_IN 12_CD -_: 16_CD ml_NN /_NN min_NN )_) contained_VBD
          most_JJS of_IN the_DT lymphocytes_NNS ._. Monocytes_NNP usually_RB appeared_VBD in_IN
          fractions_NNS 6_CD or_CC 7_CD (_( as_IN determined_VBN by_IN flow_NN cytometric_JJ
          analysis_NN in_IN a_DT fluorescence-activated_JJ cell_NN sorter_NN (_( FACS_NNP )_) ._.
          BMPCs_NNP were_VBD concentrated_VBN in_IN fractions_NNS 7_CD and_CC 8_CD ,_, along_IN with_IN
          monocytes_NNS and_CC lymphocytes_NNS ._. Elutriation_NNP fractions_NNS with_IN
          more_JJR than_IN 50_CD %_NN and_CC less_JJR than_IN 75_CD %_NN monocytes_NNS were_VBD collected_VBN
          and_CC concentrated_VBN by_IN centrifugation_NN at_IN 1200_CD rpm_NN for_IN 5_CD min_NN ,_,
          and_CC the_DT cell_NN pellets_NNS were_VBD combined_VBN ,_, reconstituted_JJ in_IN DMEM_NNP
          plus_CC 20_CD %_NN sterile_JJ heat-inactivated_JJ FCS_NNP ,_, counted_VBN ,_, washed_VBN in_IN
          medium_NN ,_, repelleted_JJ ,_, and_CC then_RB resuspended_JJ in_IN DMEM_NNP to_TO 5_CD ×_NN
          10_CD 6_CD /_NN ml_NN and_CC dispensed_VBD into_IN either_DT tissue-culture_JJ plastic_NN
          slides_NNS or_CC glass_NN chamber_NN slides_NNS ._. Cells_NNP thus_RB obtained_VBD were_VBD
          observed_VBN in_IN time-lapse_JJ cinematography_NN ,_, assayed_JJ for_IN
          proliferation_NN ,_, and_CC examined_VBD immunohistologically_RB and_CC
          histochemically_RB ,_, and_CC their_PRP$ ability_NN to_TO become_VB fibroblasts_NNS ,_,
          osteoclasts_NNS ,_, osteoblasts_NNS ,_, and_CC adipocytes_NNS was_VBD
          documented_VBN ._.
        
        
          Results_NNS
          BMPCs_NNP were_VBD found_VBN in_IN elutriation_NN fractions_NNS containing_VBG
          less_JJR than_IN 30_CD %_NN T_NN cells_NNS and_CC more_JJR than_IN 60_CD %_NN monocytes_NNS from_IN
          the_DT blood_NN of_IN more_JJR than_IN 100_CD normal_JJ persons_NNS ._. BMPCs_NNP adhered_VBD
          to_TO plastic_NN and_CC glass_NN and_CC proliferated_VBN logarithmically_RB in_IN
          DMEM-_NNP 20_CD %_NN FCS_NNP without_IN added_JJ growth_NN factors_NNS ._. The_DT initial_JJ
          elutriate_NN had_VBD only_RB small_JJ ,_, round_NN ,_, mononuclear_NN cells_NNS ;_: upon_IN
          culture_NN ,_, these_DT were_VBD replaced_VBN by_IN fibroblast-like_JJ cells_NNS and_CC
          large_JJ ,_, round_NN ,_, stromal_NN cells_NNS ._. The_DT formation_NN of_IN cells_NNS with_IN
          fibroblast-like_JJ and_CC stromal_NN morphology_NN was_VBD not_RB affected_VBN
          by_IN eliminating_VBG CD_NNP 34_CD ,_, CD_NNP 3_CD ,_, or_CC CD_NNP 14_CD cells_NNS from_IN the_DT
          elutriation_NN fraction_NN ._. Osteogenic_NNP supplements_NNS
          (_( dexamethasone_NN ,_, ascorbic_JJ acid_NN ,_, and_CC β-glycero-phosphate_JJ )_)
          added_VBD to_TO the_DT culture_NN inhibited_VBD fibroblast_NN formation_NN ,_, and_CC
          BMPCs_NNP assumed_VBD the_DT cuboidal_NN shape_NN of_IN osteoblasts_NNS ._. After_IN 5_CD
          days_NNS in_IN supplemented_JJ medium_NN ,_, the_DT elutriated_JJ cells_NNS
          displayed_VBD AP_NNP and_CC its_PRP$ production_NN was_VBD doubled_VBN by_IN the_DT
          addition_NN of_IN BMP_NN 2_CD (_( 1_CD ng_NN )_) (_( 
          P_NN <_NN 0_CD ._. 04_CD )_) ._. Two_CD weeks_NNS later_RB ,_, 30_CD %_NN
          of_IN the_DT cells_NNS were_VBD very_RB large_JJ and_CC reacted_VBD with_IN
          anti-osteocalcin_JJ antibody_NN ._. The_DT same_JJ cultures_NNS contained_VBD
          two_CD other_JJ types_NNS of_IN cell_NN :_: sudanophlic_JJ adipocytes_NNS and_CC
          multinucleated_JJ giant_NN cells_NNS ,_, which_WDT stain_VB for_IN TRAP_NNP and_CC
          vitronectin_NN receptors_NNS (_( attributes_NNS of_IN osteoclasts_NNS )_) ._.
          Cultured_NNP BMPCs_NNP were_VBD immunostained_JJ by_IN antibodies_NNS to_TO
          vimentin_NN ,_, type_NN I_PRP collagen_NN ,_, and_CC BMP_NN receptors_NNS
          (_( heterodimeric_JJ structures_NNS expressed_VBD on_IN mesenchymal_NN
          lineage_NN cells_NNS )_) ._. The_DT cultured_JJ cells_NNS also_RB stained_JJ strongly_RB
          for_IN the_DT SH-_NNP 2_CD (_( endoglin_NN )_) antigen_NN ,_, a_DT putative_JJ marker_NN for_IN
          marrow_NN MSCs_NNP ._. BMPCs_NNP express_VB the_DT gene_NN for_IN SDF-_NNP 1_CD ,_, a_DT potent_JJ
          stroma-derived_JJ CXCα_NNP chemokine_NN ._.
        
        
          Discussion_NNP
          In_IN the_DT circulation_NN of_IN normal_JJ individuals_NNS is_VBZ a_DT small_JJ
          population_NN of_IN CD_NNP 34_CD -_: mononuclear_NN cells_NNS that_WDT proliferate_VBP
          rapidly_RB in_IN culture_NN as_IN an_DT adherent_NN population_NN with_IN a_DT
          variable_JJ morphology_NN ,_, display_NN cytoskeletal_NN ,_, cytoplasmic_JJ ,_,
          and_CC surface_NN markers_NNS of_IN mesenchymal_NN precursors_NNS ,_, and_CC
          differentiate_VB into_IN several_JJ lineages_NNS (_( fibroblasts_NNS ,_,
          osteoblasts_NNS ,_, and_CC adipocytes_NNS )_) ._. These_DT are_VBP all_DT features_NNS
          found_VBD in_IN bone-marrow-derived_JJ MSCs_NNP ._. Therefore_RB ,_, autologous_JJ
          blood_NN could_MD provide_VB cells_NNS useful_JJ for_IN tissue_NN engineering_NN
          and_CC gene_NN therapy_NN ._. In_IN addition_NN ,_, the_DT demonstration_NN of_IN
          similar_JJ cells_NNS in_IN the_DT inflammatory_JJ joint_JJ fluids_NNS and_CC
          synovium_NN of_IN patients_NNS with_IN rheumatoid_NN arthritis_NN (_( RA_NNP )_)
          suggests_VBZ that_IN these_DT cells_NNS may_MD play_VB a_DT role_NN in_IN the_DT
          pathogenesis_NNS of_IN RA_NNP ._.
        
      
      
        Introduction_NNP
        Bone_NNP marrow_NN is_VBZ a_DT complex_JJ tissue_NN containing_VBG hematopoietic_JJ
        cell_NN progenitors_NNS and_CC their_PRP$ progeny_NN and_CC a_DT connective-tissue_JJ
        network_NN of_IN mesenchymally_RB derived_VBN cells_NNS known_VBN as_IN stroma_NN ._.
        Marrow_NNP stroma_NN includes_VBZ a_DT subpopulation_NN of_IN undifferentiated_JJ
        cells_NNS that_WDT are_VBP capable_JJ of_IN becoming_VBG one_CD of_IN a_DT number_NN of_IN
        phenotypes_NNS ,_, including_VBG chondrocytes_NNS ,_, osteoblasts_NNS ,_,
        adipocytes_NNS ,_, fibroblasts_NNS ,_, possibly_RB muscle_NN cells_NNS ,_, and_CC the_DT
        reticular_NN cells_NNS that_WDT support_NN hematopoietic_JJ cell_NN
        differentiation_NN [_NN 1_CD ,_, 2_CD ]_NN ._. Extensive_NNP experimentation_NN has_VBZ
        defined_VBN conditions_NNS for_IN the_DT isolation_NN ,_, propagation_NN ,_, and_CC
        differentiation_NN 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN of_IN the_DT stromal_NN cells_NNS referred_VBD
        to_TO as_IN MSCs_NNP ._. They_PRP are_VBP a_DT population_NN of_IN firmly_RB adherent_NN cells_NNS
        with_IN a_DT high_JJ proliferative_JJ capacity_NN and_CC potential_JJ for_IN
        self-renewal_JJ ._. Their_PRP$ developmental_NN potential_NN is_VBZ retained_VBN
        even_RB after_IN repeated_VBN subcultivation_NN 
        in_IN vitro_NN ,_, supporting_VBG their_PRP$
        designation_NN as_IN stem_NN cells_NNS [_NN 3_CD ]_NN ._.
        Identification_NNP of_IN MSCs_NNP 
        in_IN situ_NN has_VBZ been_VBN difficult_JJ ,_, partly_RB
        because_IN they_PRP have_VBP few_JJ unique_JJ products_NNS or_CC molecular_JJ markers_NNS ._.
        A_DT series_NN of_IN monoclonal_NN antibodies_NNS (_( SH_NNP antibodies_NNS )_)
        purportedly_RB specific_JJ reagents_NNS have_VBP been_VBN used_VBN to_TO isolate_VB
        MSCs_NNP from_IN a_DT population_NN of_IN bone-marrow_NN cells_NNS [_NN 1_CD ,_, 3_CD ]_NN ._. The_DT
        one_CD used_VBN most_RBS often_RB (_( SH-_NNP 2_LS )_) was_VBD recently_RB shown_VBN to_TO react_VB with_IN
        endoglin_NN (_( CD_NNP 105_CD )_) ,_, a_DT member_NN of_IN the_DT transforming_VBG growth_NN
        factor_NN (_( TGF_NNP )_) -_: β_NN receptor_NN family_NN usually_RB found_VBD on_IN the_DT
        endothelium_NN of_IN postcapillary_JJ venules_NNS [_NN 4_CD ]_NN ._. Two_CD other_JJ
        reagents_NNS may_MD be_VB more_RBR specific_JJ ._. One_CD consists_VBZ of_IN a_DT group_NN of_IN
        antibodies_NNS to_TO BMP_NN receptors_NNS (_( BMPRs_NNP )_) present_JJ on_IN embryonic_JJ
        mesenchyme_NN and_CC postnatally_RB on_IN osteoblasts_NNS and_CC chondrocytes_NNS
        [_NN 5_CD ]_NN ._. Another_DT antibody_NN ,_, Stro-_NNP 1_CD made_VBN against_IN marrow_NN
        fibroblastic_JJ cells_NNS ,_, blocks_NNS hematopoiesis_NNS 
        in_IN vitro_NN by_IN interfering_VBG with_IN the_DT
        interaction_NN of_IN reconstituted_JJ human_JJ hematopoietic_JJ stem_NN cells_NNS
        (_( HSCs_NNP )_) and_CC stromal_NN cells_NNS [_NN 6_CD ]_NN ._.
        Attempts_NNS to_TO demonstrate_VB MSCs_NNP in_IN peripheral_JJ blood_NN have_VBP
        been_VBN unrewarding_VBG ,_, except_IN for_IN a_DT report_NN by_IN Fernandez_NNP 
        et_CC al_NN [_NN 7_CD ]_NN ,_, who_WP identified_VBD cells_NNS with_IN
        the_DT features_NNS of_IN MSCs_NNP in_IN growth-factor-mobilized_JJ
        peripheral-blood_JJ cells_NNS from_IN breast-cancer_NN patients_NNS ._.
        Low-density_NNP mononuclear_NN cells_NNS grown_VBN for_IN 1_CD week_NN in_IN tissue_NN
        culture_NN with_IN fetal_JJ calf_NN serum_NN (_( FCS_NNP )_) become_VB adherent_NN
        fibroblast-like_JJ cells_NNS and_CC a_DT few_JJ were_VBD large_JJ ,_, flat_JJ ,_, round_NN
        cells_NNS ._. Immunohistology_NNP and_CC flow_VB cytometric_JJ analysis_NN in_IN a_DT
        fluorescence-activated_JJ cell_NN sorter_NN (_( FACS_NNP )_) revealed_VBD
        fibronectin_NN and_CC three_CD types_NNS of_IN collagen_NN (_( I_NN ,_, III_NNP ,_, and_CC VI_NNP )_) in_IN
        the_DT cytoplasm_NN of_IN the_DT cultured_JJ cells_NNS ._. They_PRP expressed_VBD
        adhesion_NN ligands_NNS and_CC antigens_NNS recognized_VBN by_IN SH-_NNP 2_CD and_CC SH-_NNP 3_CD
        monoclonal_NN antibodies_NNS ._. No_DT stromal_NN cells_NNS were_VBD demonstrated_VBN
        in_IN normal_JJ peripheral-blood_JJ cells_NNS not_RB mobilized_VBN by_IN
        granulocyte-macrophage_JJ CSF_NNP [_NN 7_CD ]_NN ._. Bucala_NNP 
        et_CC al_NN [_NN 8_CD ]_NN separated_JJ human_JJ blood_NN
        cells_NNS by_IN density_NN centrifugation_NN ,_, cultured_JJ them_PRP on_IN a_DT
        fibronectin_NN matrix_NN ,_, and_CC identified_VBD a_DT population_NN of_IN
        circulating_VBG cells_NNS that_WDT had_VBD fibroblast_NN properties_NNS and_CC a_DT
        distinctive_JJ phenotype_NN (_( collagen_NN +_NN /_NN vimentin_NN +_NN /_NN CD_NNP 34_CD +_NN )_) ._. This_DT
        novel_NN circulating_VBG cell_NN ,_, termed_VBD a_DT fibrocyte_NN ,_, has_VBZ both_DT
        mesenchymal_NN and_CC hematopoietic_JJ features_NNS ._.
        Now_RB we_PRP report_VBP for_IN the_DT first_JJ time_NN that_IN cells_NNS with_IN the_DT
        morphology_NN and_CC phenotype_NN of_IN mesenchymal_NN precursors_NNS are_VBP
        normally_RB present_JJ in_IN the_DT circulation_NN ._. Hereafter_NNP these_DT are_VBP
        referred_VBN to_TO as_IN `_`` blood-derived_JJ mesenchymal_NN precursor_NN cells_NNS '_POS
        (_( BMPCs_NNP )_) ._. The_DT observations_NNS that_WDT support_NN these_DT conclusions_NNS
        and_CC the_DT significance_NN of_IN the_DT findings_NNS are_VBP discussed_VBN ._.
      
      
        Methods_NNP
        
          Reagents_NNP and_CC laboratory_NN ware_NN
          Dexamethasone_NNP ,_, ascorbic_JJ acid-_NN 2_CD phosphate_NN ,_,
          β-glycerophosphate_JJ ,_, bovine_JJ serum_NN albumin_NN (_( BSA_NNP )_) ,_, and_CC FCS_NNP
          were_VBD purchased_VBN from_IN Sigma_NNP Diagnostics_NNPS (_( St_NNP Louis_NNP ,_, MO_NNP ,_,
          USA_NNP )_) ;_: penicillin_NN ,_, streptomycin_NN ,_, DMEM_NNP ,_, and_CC RPMI-_NNP 1640_CD from_IN
          Biowhittaker_NNP (_( Watersville_NNP ,_, MD_NNP ,_, USA_NNP )_) ;_: Lymphoprep_NNP ™_NN from_IN
          Nycomed_NNP ,_, Oslo_NNP ,_, Norway_NNP ._.
          Monoclonal_NNP antibodies_NNS were_VBD purchased_VBN from_IN commercial_JJ
          vendors_NNS unless_IN otherwise_RB stated_VBN :_: CD_NNP 3_CD ,_, IgG_NNP 1_CD ;_: CD_NNP 68_CD ,_, IgG_NNP 1_CD ;_:
          CD_NNP 34_CD ,_, IgG_NNP 1_CD ;_: CD_NNP 45_CD ,_, IgG_NNP 1_CD ,_, D_NNP 105_CD ,_, IgG_NNP 1_CD ;_: and_CC IgG_NNP 2_CD a_DT controls_NNS
          (_( Dako_NNP Corporation_NNP ,_, Carpinteria_NNP ,_, CA_NNP ,_, USA_NNP )_) ;_: anti-_NN HLA-DR_NNP ,_,
          IgG_NNP 2_CD a_SYM ;_: CD_NNP 14_CD ,_, IgG_NNP 2_CD b_SYM ;_: CD_NNP 34_CD ,_, IgG_NNP 1_CD (_( Becton_NNP Dickinson_NNP ,_, San_NNP
          Jose_NNP ,_, CA_NNP ,_, USA_NNP )_) ;_: anti-vimentin_JJ ,_, IgG_NNP 1_CD ;_: IgG_NNP 2_CD b_SYM control_NN
          (_( Serotec_NNP ,_, Kidlington_NNP ,_, Oxfordshire_NNP ,_, UK_NNP )_) ;_: anti-_NN VCAM-_NNP 1_CD ,_,
          IgG_NNP 1_CD ;_: anti-αvβ_JJ 3_CD (_( vitronectin_NN receptor_NN )_) ,_, IgG_NNP 1_CD (_( Pharmingen_NNP ,_,
          San_NNP Diego_NNP ,_, CA_NNP ,_, USA_NNP )_) ;_: anti-collagen-type-_JJ 1_CD ,_, IgG_NNP 1_CD (_( Sigma_NNP
          Diagnostics_NNPS )_) ;_: anti-osteocalcin_JJ ,_, IgG_NNP 1_CD (_( ABOC-_NNP 5021_CD ,_,
          Haematologic_NNP Technologies_NNPS ,_, Essex_NNP Junction_NNP ,_, VT_NNP ,_, USA_NNP )_)
          anti-_NN IgG_NNP 1_CD ._. Stro-_NNP 1_CD is_VBZ a_DT culture_NN supernatant_NN ,_, monoclonal_NN
          IgM_NNP ,_, from_IN Developmental_NNP Studies_NNPS Hybridoma_NNP Bank_NNP ,_,
          University_NNP of_IN Iowa_NNP (_( Iowa_NNP City_NNP ,_, IA_NNP ,_, USA_NNP )_) ._. Biotinylated_NNP
          mouse_NN Ig_NNP ,_, streptavidin_NN /_NN horseradish_NN peroxidase_NN conjugate_NN ,_,
          diamino_NN benzidine_NN ,_, and_CC Vectastain_NNP ABC_NNP were_VBD from_IN Vector_NNP
          (_( Burlingame_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
          Tissue-culture_NNP treated_VBD glass_NN slides_NNS ,_, Petri_NNP dishes_NNS ,_, and_CC
          six-well_JJ tissue-culture_JJ plates_NNS and_CC eight-chamber_JJ tissue_NN
          culture_NN slides_NNS (_( Falcon_NNP )_) were_VBD from_IN Becton_NNP Dickinson_NNP
          Labware_NNP (_( Franklin_NNP Lakes_NNP ,_, NJ_NNP ,_, USA_NNP )_) ;_: 12_CD -_: well_RB sterile_JJ glass_NN
          slides_NNS were_VBD from_IN ICN_NNP (_( Costa_NNP Mesa_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
        
          Elutriation_NNP procedure_NN for_IN BMPCs_NNP
          Anticoagulant-treated_NNP ,_, platelet-depleted_JJ buffy_NN coat_NN
          was_VBD obtained_VBN in_IN sterile_JJ packages_NNS from_IN the_DT North_NNP London_NNP
          Blood_NNP Transfusion_NNP Service_NNP ._. About_IN 50_CD ml_NN of_IN the_DT buffy_NN coat_NN
          was_VBD diluted_VBN 1_CD :_: 4_CD in_IN RPMI_NNP and_CC 25_CD ml_NN was_VBD layered_JJ over_IN 20_CD ml_NN
          of_IN Lymphoprep_NNP ™_NN in_IN a_DT 50_CD -_: ml_NN conical_JJ centrifuge_NN tube_NN ._. The_DT
          tubes_NNS (_( approximately_RB eight_CD )_) were_VBD centrifuged_JJ at_IN 2000_CD rpm_NN
          for_IN 20_CD min_NN ._. The_DT supernatant_NN was_VBD discarded_VBN and_CC
          leukocyte-rich_JJ interface_NN cells_NNS were_VBD collected_VBN and_CC
          combined_VBN ._. These_DT were_VBD made_VBN up_IN to_TO 20_CD ml_NN in_IN RPMI_NNP and_CC layered_JJ
          again_RB over_IN Lymphoprep_NNP ™_NN and_CC centrifuged_JJ at_IN 2000_CD rpm_NN for_IN 20_CD
          min_NN more_RBR ._. The_DT buffy_NN coat_NN ,_, now_RB depleted_VBN of_IN red_JJ blood_NN
          cells_NNS ,_, was_VBD collected_VBN from_IN the_DT interface_NN ,_, resuspended_JJ in_IN
          50_CD ml_NN of_IN sterile_JJ RMPI_NNP and_CC 5_CD %_NN heat-inactivated_JJ FCS_NNP ,_, and_CC
          introduced_VBD into_IN the_DT sample_NN line_NN of_IN the_DT flow_NN system_NN of_IN a_DT
          Beckman_NNP JE-_NNP 50_CD cell_NN elutriator_NN which_WDT had_VBD been_VBN charged_VBN with_IN
          elutriation_NN buffer_NN ._. The_DT chamber_NN was_VBD centrifuged_JJ at_IN 25_CD 000_CD
          rpm_NN at_IN 10_CD °_NN C_NNP and_CC the_DT flow_NN rate_NN adjusted_VBN to_TO 12_CD ml_NN /_NN min_NN ._. The_DT
          eluate_NN fractions_NNS were_VBD collected_VBN in_IN sterile_JJ ,_, conical_JJ ,_,
          50_CD -_: ml_NN tubes_NNS ._. After_IN about_IN 150_CD ml_NN had_VBD been_VBN collected_VBN ,_, the_DT
          flow_NN rate_NN was_VBD increased_VBN by_IN 1_CD ml_NN /_NN min_NN ._. Fractions_NNP nos_NNS ._. 1_LS -_: 6_CD
          (_( flow_NN rates_NNS of_IN 12_CD -_: 16_CD ml_NN /_NN min_NN )_) contained_VBD most_JJS of_IN the_DT
          lymphocytes_NNS ._. Monocytes_NNP usually_RB made_VBD their_PRP$ appearance_NN (_( as_IN
          determined_VBN by_IN FACS_NNP analysis_NN )_) in_IN fraction_NN 6_CD or_CC 7_CD ._. In_IN
          fractions_NNS 7_CD and_CC 8_CD ,_, monocytes_NNS constituted_VBD up_IN to_TO two_CD thirds_NNS
          of_IN the_DT cells_NNS ,_, and_CC BMPCs_NNP were_VBD concentrated_VBN in_IN these_DT
          fractions_NNS ._. Elutriation_NNP fractions_NNS containing_VBG more_JJR than_IN 50_CD %_NN
          and_CC less_JJR than_IN 75_CD %_NN monocytes_NNS were_VBD concentrated_VBN by_IN
          centrifugation_NN at_IN 1200_CD rpm_NN for_IN 5_CD min_NN ,_, and_CC the_DT cell_NN
          pellets_NNS were_VBD combined_VBN ,_, reconstituted_JJ in_IN DMEM_NNP plus_CC 20_CD %_NN
          sterile_JJ heat-inactivated_JJ FCS_NNP (_( hereafter_RB referred_VBD to_TO as_IN
          complete_JJ medium_NN ,_, unless_IN otherwise_RB stated_VBN )_) ,_, counted_VBN in_IN a_DT
          hemocytometer_NN ,_, washed_VBN in_IN DMEM_NNP medium_NN ,_, repelleted_JJ ,_,
          resuspended_JJ to_TO 5_CD ×_NN 10_CD 6_CD /_NN ml_NN ,_, and_CC dispensed_VBD into_IN either_DT
          plastic_NN tissue-culture_JJ slides_NNS or_CC glass_NN chamber_NN
          slides_NNS ._.
          More_JJR than_IN 100_CD consecutive_JJ buffy_NN coats_NNS from_IN normal_JJ
          individuals_NNS were_VBD processed_VBN by_IN this_DT method_NN and_CC cultured_JJ ._.
          In_IN every_DT case_NN ,_, the_DT appropriate_JJ elutriation_NN fractions_NNS had_VBD
          cells_NNS with_IN the_DT BMPC_NNP morphology_NN ._.
        
        
          Cell-proliferation_NNP assay_NN
          The_DT BMPC-rich_NNP elutriation_NN fractions_NNS were_VBD plated_JJ at_IN 5_CD ×_NN
          10_CD 5_CD in_IN 500_CD μl_NN of_IN complete_JJ medium_NN in_IN polystyrene_NN chambers_NNS
          on_IN treated_VBN glass_NN tissue-culture_JJ slides_NNS (_( Falcon_NNP )_) ._. At_IN
          various_JJ times_NNS ,_, cultures_NNS were_VBD rinsed_JJ twice_RB with_IN Tyrode_NNP 's_POS
          balanced_JJ salt_NN solution_NN ,_, fixed_VBN with_IN 1_CD %_NN glutaraldehyde_NN
          (_( v_NN /_NN v_NN )_) in_IN Tyrode_NNP 's_POS for_IN 15_CD min_NN ,_, rinsed_JJ twice_RB with_IN deionized_JJ
          water_NN ,_, and_CC air-dried_JJ ._. Cultures_NNP were_VBD then_RB stained_JJ with_IN
          0_CD ._. 1_CD %_NN crystal_NN violet_NN (_( w_NN /_NN v_NN )_) in_IN deionized_JJ water_NN for_IN 30_CD min_NN
          and_CC washed_VBN 3_CD times_NNS with_IN deionized_JJ water_NN ;_: the_DT
          crystal-violet_JJ dye_NN was_VBD extracted_VBN by_IN rocking_VBG the_DT cultures_NNS
          gently_RB in_IN 1_CD %_NN Triton_NNP X-_NNP 100_CD for_IN 4_CD h_NN at_IN room_NN temperature_NN and_CC
          read_VB at_IN 595_CD nm_NN on_IN a_DT microplate_NN reader_NN (_( BioRad_NNP ,_, Hercules_NNP ,_,
          CA_NNP ,_, USA_NNP )_) ._. Absorbance_NNP values_NNS (_( optical_JJ densities_NNS ;_: ODs_NNP )_) were_VBD
          converted_VBN into_IN absolute_JJ cell_NN numbers_NNS on_IN the_DT basis_NN of_IN
          established_VBN standard_JJ curves_NNS [_NN 9_CD ]_NN ._.
        
        
          Immunohistochemistry_NNP
          BMPC-rich_NNP elutriation_NN fractions_NNS (_( 500_CD μl_NN ,_, containing_VBG 5_CD
          ×_NN 10_CD 6_CD cells_NNS per_IN ml_NN )_) or_CC other_JJ sources_NNS of_IN BMPCs_NNP were_VBD placed_VBN
          into_IN the_DT wells_NNS of_IN sterile_JJ ,_, 12_CD -_: well_RB multitest_NN slides_NNS (_( ICN_NNP )_)
          in_IN complete_JJ medium_NN and_CC left_VBD to_TO adhere_VB at_IN 37_CD °_NN C_NNP for_IN 4_CD h_NN ._.
          The_DT slides_NNS were_VBD then_RB placed_VBN into_IN 100_CD ×_NN 20_CD mm_NN Petri_NNP dishes_NNS
          containing_VBG 5_CD -_: 7_CD ml_NN DMEM-_NNP 20_CD %_NN FCS_NNP ._. The_DT nonadherent_NN cells_NNS
          floated_VBD off_RP ,_, while_IN mesenchymal_NN cells_NNS adhered_VBD ,_, spread_NN ,_, and_CC
          grew_VBD ._. Their_PRP$ daily_JJ progress_NN was_VBD assessed_VBN by_IN phase-contrast_JJ
          microscopy_NN ._. The_DT medium_NN was_VBD changed_VBN every_DT 3_CD to_TO 5_CD days_NNS and_CC
          the_DT cells_NNS were_VBD studied_VBN after_IN 5_CD -_: 7_CD days_NNS ._. The_DT growing_VBG ,_,
          adherent_NN cells_NNS were_VBD rinsed_JJ in_IN phosphate-buffered_JJ saline_NN
          (_( PBS_NNP )_) ,_, fixed_VBN in_IN ice-cold_JJ 4_CD %_NN paraformaldehyde_NN for_IN 20_CD min_NN ,_,
          and_CC then_RB washed_VBN in_IN PBS_NNP ._. All_DT further_JJ incubations_NNS and_CC
          washes_NNS were_VBD carried_VBN out_IN using_VBG PBS_NNP ._. Endogenous_NNP peroxidase_NN
          activity_NN was_VBD blocked_VBN with_IN 0_CD ._. 1_CD mol_NN sodium_NN azide_NN containing_VBG
          1_CD %_NN hydrogen_NN peroxide_NN ,_, and_CC the_DT specimens_NNS were_VBD incubated_JJ
          with_IN 10_CD %_NN normal_JJ goat_NN serum_NN ,_, 2_CD %_NN normal_JJ rat_NN serum_NN ,_, and_CC 1_CD %_NN
          bovine_JJ serum_NN albumin_NN for_IN 30_CD min_NN at_IN room_NN temperature_NN to_TO
          eliminate_VB non-specific_JJ binding_JJ ._. Specimens_NNP were_VBD then_RB
          incubated_JJ with_IN primary_JJ antibodies_NNS at_IN 4_CD °_NN C_NNP overnight_JJ and_CC
          were_VBD then_RB incubated_JJ with_IN a_DT biotinylated_JJ secondary_JJ
          antibody_NN (_( Vector_NNP )_) ._. The_DT antibody-biotin_JJ conjugates_NNS were_VBD
          detected_VBN with_IN an_DT avidin-biotin-peroxidase_JJ complex_JJ
          (_( Vector_NNP )_) ,_, applied_VBN for_IN 30_CD min_NN at_IN room_NN temperature_NN ._. A_DT color_NN
          reaction_NN was_VBD developed_VBN with_IN 3_CD -_: amino-_NN 9_CD -_: ethylcarbazole_NN and_CC
          specimens_NNS were_VBD lightly_RB counterstained_JJ with_IN Mayer_NNP 's_POS
          hematoxylin_NN ._.
          Controls_NNP included_VBD normal_JJ rabbit_NN or_CC mouse_NN IgG_NNP ,_, 1_CD %_NN BSA_NNP
          in_IN PBS_NNP ,_, or_CC ,_, in_IN the_DT case_NN of_IN BMPR_NNP antibodies_NNS ,_, preabsorbed_JJ
          with_IN the_DT respective_JJ peptide_NN used_VBN for_IN immunization_NN ._.
        
        
          Quantification_NNP of_IN BMPCs_NNP by_IN
          immunohistochemistry_NN
          BMPC-rich_NNP elutriation_NN fractions_NNS (_( 5_CD ×_NN 10_CD 5_CD cells_NNS in_IN 500_CD
          μl_NN of_IN complete_JJ medium_NN )_) were_VBD placed_VBN into_IN the_DT chambers_NNS of_IN
          sterile_JJ ,_, eight-chamber_JJ ,_, treated_VBN glass_NN tissue-culture_JJ
          slides_NNS ._. Two_CD to_TO 4_CD h_NN later_RB ,_, nonadherent_NN cells_NNS were_VBD removed_VBN ._.
          Cultures_NNP were_VBD fed_VBN every_DT 3_CD days_NNS ._. At_IN regular_JJ intervals_NNS ,_, the_DT
          slides_NNS were_VBD rinsed_JJ in_IN PBS_NNP ,_, fixed_VBN in_IN ice-cold_JJ 4_CD %_NN
          paraformaldehyde_NN for_IN 20_CD min_NN ,_, washed_VBN in_IN PBS_NNP ,_, stained_JJ with_IN
          anti-_NN BMPR_NNP antibodies_NNS ,_, and_CC visualized_JJ by_IN the_DT ABC_NNP
          immunoperoxidase_NN method_NN described_VBD above_IN ._. The_DT specimens_NNS
          were_VBD examined_VBN using_VBG an_DT Olympus_NNP BH-_NNP 2_CD microscope_NN and_CC
          analyzed_VBN by_IN computer_NN image_NN analysis_NN (_( AnalySIS_NNP ,_, Soft_NNP
          Imaging_NNP System_NNP GmbH_NNP ,_, Münster_NNP ,_, Germany_NNP )_) ._. Six_CD digital_JJ
          images_NNS (_( 400_CD ×_NN )_) per_IN specimen_NN were_VBD recorded_VBN and_CC quantitative_JJ
          analysis_NN was_VBD performed_VBN according_VBG to_TO the_DT color_NN cell_NN
          separation_NN ._. Images_NNP chosen_VBN at_IN random_JJ were_VBD analyzed_VBN and_CC the_DT
          data_NNS are_VBP presented_VBN as_IN the_DT mean_NN of_IN the_DT total_JJ number_NN of_IN
          cells_NNS per_IN six_CD images_NNS examined_VBD at_IN 400_CD ×_NN ._. Slender_NNP cells_NNS with_IN
          a_DT small_JJ ,_, centrally_RB localized_JJ nucleus_NN were_VBD scored_VBN as_IN
          fibroblast-like_JJ ._. Large_JJ ,_, round_NN cells_NNS and_CC
          intermediate-sized_JJ cells_NNS with_IN more_JJR cytoplasm_NN and_CC a_DT large_JJ ,_,
          round_NN nucleus_NN were_VBD scored_VBN as_IN large_JJ cells_NNS ._.
        
        
          Anti-_NNP BMPR_NNP antibodies_NNS
          Rabbit_NNP polyclonal_NN antibodies_NNS to_TO BMPRs_NNP were_VBD provided_VBN by_IN
          K_NNP Funa_NNP (_( Göteborg_NNP University_NNP ,_, Gothenburg_NNP ,_, Sweden_NNP )_) ._.
          Polyclonal_NNP rabbit_NN antisera_NN were_VBD prepared_VBN using_VBG synthetic_JJ
          peptides_NNS corresponding_JJ to_TO the_DT intracellular_NN transmembrane_NN
          portions_NNS of_IN the_DT types_NNS IA_NNP ,_, IB_NNP ,_, and_CC II_NNP BMPRs_NNP [_NN 10_CD ]_NN ._. The_DT
          antisera_NN were_VBD affinity-purified_JJ and_CC tested_VBN for_IN
          specificity_NN by_IN immunoprecipitation_NN of_IN cross-linked_JJ
          complexes_NNS of_IN cultured_JJ cells_NNS transfected_JJ with_IN receptor_NN
          complementary_JJ deoxyribonucleic_JJ acids_NNS (_( cDNAs_NNS )_) [_NN 11_CD ]_NN ._.
          Magnetic_JJ antibody-coated-bead_JJ separation_NN (_( MACS_NNP )_) was_VBD
          performed_VBN in_IN accordance_NN with_IN the_DT manufacturer_NN 's_POS
          recommendations_NNS (_( Miltenyi_NNP Biotec_NNP ,_, Inc_NNP ._. ,_, Auburn_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
          Elutriation_NNP fractions_NNS with_IN 50_CD -_: 75_CD %_NN monocytes_NNS were_VBD
          centrifuged_JJ at_IN 900_CD ×_NN 
          
            g_SYM 
           ,_, washed_VBN with_IN MACS_NNP buffer_NN (_( PBS_NNP pH_NN 7_CD ._. 2_LS ,_, +_NN 0_CD ._. 5_CD %_NN SSA_NNP +_NN 2_CD
          mmol_NN EDTA_NNP )_) and_CC counted_VBN in_IN a_DT hemocytometer_NN ._. The_DT cell_NN
          pellet_NN was_VBD resuspended_JJ in_IN 80_CD μl_NN MACS_NNP buffer_NN per_IN 10_CD 7_CD total_JJ
          cells_NNS ,_, and_CC 20_CD μl_NN of_IN MACS_NNP antibody-coated_JJ beads_NNS was_VBD added_VBN
          to_TO the_DT cells_NNS ,_, mixed_JJ ,_, and_CC incubated_JJ for_IN 15_CD min_NN at_IN 6_CD -_: 12_CD °_NN C_NNP ._.
          The_DT cells_NNS were_VBD washed_VBN with_IN a_DT 20_CD -_: fold_VB volume_NN of_IN MACS_NNP
          buffer_NN ,_, spun_VBN ,_, and_CC resus-pended_JJ in_IN 500_CD μl_NN buffer_NN ._. The_DT cell_NN
          suspension_NN was_VBD applied_VBN to_TO a_DT positive_JJ selection_NN column_NN
          washed_VBN previously_RB with_IN 1_CD ml_NN MACS_NNP buffer_NN and_CC placed_VBN in_IN a_DT
          magnetic_JJ separator_NN and_CC the_DT cells_NNS were_VBD eluted_JJ ._. The_DT column_NN
          was_VBD rinsed_JJ four_CD times_NNS with_IN 500_CD μl_NN buffer_NN and_CC the_DT cells_NNS
          that_WDT passed_VBD through_IN were_VBD combined_VBN as_IN the_DT antigen-free_JJ
          fraction_NN ._. The_DT column_NN was_VBD removed_VBN from_IN the_DT magnetic_JJ
          separator_NN ,_, 1_CD ml_NN of_IN buffer_NN was_VBD added_VBN to_TO the_DT column_NN ,_, and_CC
          the_DT positive_JJ cells_NNS were_VBD flushed_JJ out_IN with_IN a_DT syringe_NN
          plunger_NN ._. This_DT was_VBD repeated_VBN with_IN another_DT 1_CD ml_NN of_IN buffer_NN ._.
          The_DT elutriated_JJ cells_NNS were_VBD combined_VBN as_IN the_DT
          antigen-containing_JJ fraction_NN ._.
        
        
          Alkaline_NNP phosphatase_NN activity_NN of_IN circulating_VBG
          BMPCs_NNP
          BMPC-rich_NNP elutriation_NN fractions_NNS were_VBD prepared_VBN from_IN
          four_CD individual_JJ blood_NN packs_NNS as_IN described_VBN and_CC plated_JJ into_IN
          four-well_JJ chamber_NN slides_NNS (_( Lab-_NNP Tek_NNP )_) at_IN 5_CD ×_NN 10_CD 6_CD cells_NNS per_IN
          ml_NN in_IN DMEM-_NNP 10_CD %_NN FCS_NNP ._. After_IN 24_CD h_NN at_IN 37_CD °_NN C_NNP ,_, the_DT nonadherent_NN
          cells_NNS were_VBD removed_VBN and_CC new_JJ medium_NN was_VBD added_VBN containing_VBG
          BMP_NN 2_CD (_( a_DT gift_NN from_IN the_DT Genetics_NNP Institute_NNP ,_, Cambridge_NNP ,_, MA_NNP ,_,
          USA_NNP )_) at_IN concentrations_NNS of_IN 0_CD ,_, 1_CD ,_, 10_CD ,_, or_CC 100_CD ng_NN /_NN ml_NN ._. The_DT
          cells_NNS were_VBD incubated_JJ at_IN 37_CD °_NN C_NNP in_IN 5_CD %_NN CO_NNP 
          2_CD and_CC the_DT medium_NN was_VBD changed_VBN every_DT 5_CD
          days_NNS ._. Supernatants_NNP were_VBD taken_VBN at_IN 5_CD ,_, 10_CD ,_, and_CC 15_CD days_NNS and_CC
          stored_VBD at_IN -_: 20_CD °_NN C_NNP for_IN later_RB analysis_NN ._. AP_NNP activity_NN in_IN the_DT
          supernatants_NNS was_VBD estimated_VBN using_VBG a_DT 
          p_NN -_: nitro-phenol_JJ colorimetric_JJ assay_NN ._.
          Cell_NNP supernatants_NNS were_VBD assayed_JJ for_IN AP_NNP activity_NN in_IN 50_CD mmol_NN
          glycine_NN ,_, 0_CD ._. 05_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 4_CD mmol_NN MgCl_NNP 
          2_CD ,_, and_CC 5_CD mmol_NN 
          p_NN -_: nitrophenol_NN phosphate_NN ,_, pH_NN 10_CD ._. 3_LS ,_,
          for_IN 15_CD min_NN at_IN 37_CD °_NN C_NNP (_( Sigma_NNP Diagnostics_NNPS ,_, St_NNP Louis_NNP ,_, MO_NNP )_) ._. OD_NNP
          was_VBD measured_VBN at_IN 405_CD nm_NN and_CC compared_VBN with_IN that_DT of_IN
          standards_NNS ._.
        
        
          Stromal-cell-derived_NNP factor_NN (_( SDF_NNP )_) -_: 1_CD RT-PCR_NNP
          RNA_NNP was_VBD isolated_VBN from_IN BMPCs_NNP cultured_JJ for_IN 7_CD -_: 12_CD days_NNS
          using_VBG the_DT Qiagen_NNP RN_NNP Easy_NNP kit_NN (_( Qiagen_NNP ,_, Santa_NNP Clarita_NNP ,_, CA_NNP ,_,
          USA_NNP )_) ._. RNA_NNP was_VBD then_RB used_VBN for_IN the_DT first-strand_JJ cDNA_NN
          synthesis_NN in_IN the_DT SuperScript_NNP Preamplification_NNP System_NNP
          (_( GIBCO_NNP ,_, BRL_NNP ,_, Rockville_NNP ,_, MD_NNP ,_, USA_NNP )_) in_IN accordance_NN with_IN the_DT
          manufacturer_NN 's_POS instructions_NNS ._. SDF-_NNP 1_CD specific_JJ primers_NNS :_:
          5_CD '_POS -_: GAGGATCCGACGGGAAGCCC-GTCAGC_NNP ;_:
          3_CD '_POS -_: GAA-TTCACATCTTGAACCTCTTG_NNP ._. The_DT annealing_VBG temperature_NN
          was_VBD 58_CD °_NN C_NNP and_CC the_DT reaction_NN proceeded_VBD for_IN 35_CD cycles_NNS ._. The_DT
          glyceraldehyde-_NN 3_CD -_: phosphate_NN dehydrogenase_NN (_( GA_NNP 3_CD PD_NNP )_) gene_NN was_VBD
          included_VBN as_IN a_DT reverse_JJ transcriptase_NN polymerase_NN chain_NN
          reaction_NN (_( RT-PCR_NNP )_) control_NN and_CC performed_VBN under_IN similar_JJ
          conditions_NNS to_TO normalize_VB for_IN the_DT amount_NN of_IN RNA_NNP ._. Reaction_NNP
          products_NNS were_VBD analyzed_VBN in_IN 2_CD %_NN agarose_NN gel_NN containing_VBG 0_CD ._. 25_CD
          mg_NN /_NN ml_NN ethidium_NN bromide_NN ._.
        
        
          Data_NNP analysis_NN and_CC statistics_NNS
          Results_NNS are_VBP shown_VBN as_IN the_DT standard_JJ error_NN about_IN the_DT mean_NN
          (_( SEM_NNP )_) of_IN at_IN least_JJS three_CD experiments_NNS each_DT ._. For_IN statistical_JJ
          comparison_NN between_IN groups_NNS ,_, the_DT Student_NNP paired_VBN 
          t_NN test_NN or_CC Bonferroni_NNP 
          t_NN test_NN was_VBD used_VBN ._. Analyses_NNS were_VBD
          performed_VBN using_VBG the_DT Biostatistics_NNP software_NN developed_VBN by_IN
          Stanton_NNP A_DT Glantz_NNP (_( UC_NNP San_NNP Francisco_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Flow_NNP
          cytometry_NN data_NNS were_VBD analyzed_VBN using_VBG the_DT FlowJo_NNP
          software_NN ._.
        
      
      
        Results_NNS
        
          BMPCs_NNP selected_VBN by_IN elutriation_NN of_IN normal_JJ human_JJ
          blood_NN
          When_WRB the_DT elutriated_JJ cells_NNS from_IN the_DT fractions_NNS between_IN
          the_DT smaller_JJR T_NN cells_NNS and_CC the_DT larger_JJR ,_, more_RBR granular_JJ
          monocytes_NNS were_VBD cultured_JJ in_IN complete_JJ medium_NN without_IN any_DT
          other_JJ supplements_NNS ,_, they_PRP appeared_VBD small_JJ and_CC round_NN on_IN
          examination_NN by_IN phase-contrast_JJ microscopy_NN ._. Some_DT of_IN them_PRP
          were_VBD nonadherent_NN (_( presumably_RB T_NN lymphocytes_NNS )_) and_CC were_VBD
          removed_VBN with_IN the_DT initial_JJ feeding_NN of_IN the_DT culture_NN ._. After_IN 72_CD
          h_NN ,_, elongated_JJ cells_NNS with_IN a_DT fibroblast-like_JJ morphology_NN and_CC
          large_JJ cells_NNS with_IN a_DT clear_JJ ,_, thin_JJ ,_, adherent_NN cytoplasm_NN around_IN
          a_DT central_JJ nucleus_NN made_VBD their_PRP$ appearance_NN ._. Over_IN the_DT ensuing_VBG
          7_CD -_: 14_CD days_NNS ,_, they_PRP became_VBD the_DT predominant_NN cells_NNS in_IN the_DT
          culture_NN (_( Fig_NNP ._. 1_LS a_DT )_) ._. At_IN higher_JJR magnification_NN they_PRP could_MD
          often_RB be_VB seen_VBN to_TO have_VB a_DT splayed_JJ ,_, spreading_VBG cap_NN at_IN the_DT end_NN
          and_CC a_DT small_JJ ,_, central_JJ nucleus_NN ._. Another_DT cell_NN population_NN ,_,
          consisting_VBG of_IN larger_JJR and_CC wider_JJR cells_NNS ,_, with_IN more_JJR cytoplasm_NN
          and_CC a_DT larger_JJR nucleus_NN ,_, was_VBD intermediate_JJ in_IN morphology_NN
          between_IN the_DT large_JJ ,_, round_NN cells_NNS and_CC the_DT thinner_JJR ,_,
          fibroblast-like_JJ cells_NNS (_( Fig_NNP ._. 1_LS b_SYM )_) ._. Culture_NNP conditions_NNS
          modified_VBN the_DT morphology_NN of_IN the_DT elutriated_JJ cells_NNS ._. Adding_VBG
          dexamethasone_NN (_( 100_CD nmol_NN )_) at_IN the_DT initiation_NN of_IN the_DT culture_NN
          significantly_RB reduced_VBD (_( by_IN 60_CD %_NN ±_NN 10_CD %_NN )_) the_DT total_JJ number_NN of_IN
          cells_NNS at_IN the_DT 7_CD th_NN to_TO 10_CD th_NN days_NNS and_CC decreased_VBD the_DT formation_NN
          of_IN fibroblast-like_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._. Cultures_NNP
          supplemented_JJ with_IN a_DT mixture_NN of_IN 100_CD nmol_NN dexamethasone_NN ,_,
          0_CD ._. 05_CD mmol_NN ascorbic_JJ acid-_NN 2_CD -_: phosphate_NN ,_, and_CC 10_CD mmol_NN
          β-glycerophosphate_JJ (_( conditions_NNS that_WDT favor_NN the_DT development_NN
          of_IN osteoblasts_NNS )_) developed_VBN only_RB round_NN or_CC cuboidal_NN cells_NNS ,_,
          and_CC not_RB fibroblast-like_JJ ones_NNS (_( Fig_NNP ._. 1_LS c_SYM )_) ._. Dexamethasone_NNP
          alone_RB added_VBD at_IN days_NNS 6_CD to_TO 8_CD reduced_VBN fibroblast_NN numbers_NNS ,_,
          but_CC not_RB the_DT total_JJ cell_NN numbers_NNS (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          BMPC-rich_NNP elutriation_NN fractions_NNS observed_VBD in_IN
          time-lapse_JJ cinematography_NN
          Clusters_NNP of_IN small_JJ round_NN cells_NNS formed_VBN within_IN 24_CD h_NN ._. Cell_NNP
          processes_VBZ occasionally_RB extended_VBN from_IN them_PRP ,_, but_CC these_DT
          retracted_VBD minutes_NNS later_RB (_( Fig_NNP ._. 2_LS a_DT )_) ._. Individual_JJ cells_NNS were_VBD
          motile_NN and_CC often_RB left_VBD the_DT field_NN ,_, but_CC the_DT clusters_NNS
          remained_VBD intact_JJ ._. After_IN 72_CD h_NN ,_, a_DT few_JJ cells_NNS with_IN a_DT
          fibroblast-like_JJ morphology_NN could_MD be_VB seen_VBN beneath_IN and_CC at_IN
          the_DT edges_NNS of_IN the_DT clusters_NNS ._. The_DT fibroblast-like_JJ cells_NNS were_VBD
          much_RB larger_JJR than_IN the_DT initial_JJ cells_NNS and_CC quite_RB mobile_JJ ,_,
          extending_VBG and_CC retracting_VBG usually_RB about_IN a_DT broad_JJ ,_, fixed_VBN
          cup_NN ,_, or_CC pseudopod_NN ._. By_IN 6_CD days_NNS ,_, a_DT significant_JJ portion_NN of_IN
          the_DT cells_NNS retained_VBD their_PRP$ elongated_JJ form_NN and_CC looked_VBD like_IN
          the_DT cells_NNS in_IN Fig_NNP ._. 2_LS b_SYM ._. Large_JJ ,_, round_NN cells_NNS were_VBD also_RB
          present_JJ ._. Thus_RB ,_, it_PRP appears_VBZ that_IN BMPCs_NNP in_IN the_DT circulation_NN
          were_VBD present_JJ as_IN small_JJ ,_, round_NN mononuclear_NN cells_NNS and_CC their_PRP$
          subsequent_JJ morphology_NN and_CC function_NN were_VBD dictated_VBN by_IN
          culture_NN conditions_NNS ._.
        
        
          Cell_NNP numbers_NNS in_IN the_DT BMPC-rich_NNP elutriation_NN fraction_NN
          from_IN 500_CD ml_NN of_IN normal_JJ human_JJ blood_NN
          Elutriation_NNP fractions_NNS were_VBD selected_VBN for_IN quantification_NN
          of_IN BMPCs_NNP based_VBN on_IN cell_NN size_NN (_( intermediate_JJ between_IN
          lymphocytes_NNS and_CC monocytes_NNS )_) and_CC granularity_NN (_( FACS_NNP )_) ._. This_DT
          population_NN comprised_VBN less_JJR than_IN 35_CD %_NN lymphocytes_NNS and_CC more_JJR
          than_IN 50_CD %_NN monocytes_NNS ._. Nineteen_NNP consecutive_JJ samples_NNS had_VBD an_DT
          average_JJ total_JJ cell_NN number_NN of_IN 2_CD ._. 14_CD ±_NN 0_CD ._. 22_CD (_( SEM_NNP )_) ×_NN 10_CD 7_CD ,_, of_IN
          which_WDT 64_CD ._. 4_LS %_NN ±_NN 1_CD ._. 5_CD %_NN (_( SEM_NNP )_) were_VBD monocytes_NNS ._. A_DT
          sub-population_JJ ,_, estimated_VBN as_IN 0_CD ._. 3_CD -_: 0_CD ._. 7_CD %_NN of_IN the_DT starting_VBG
          elutriation_NN fractions_NNS ,_, was_VBD judged_VBN to_TO consist_VB of_IN BMPCs_NNP on_IN
          the_DT basis_NN of_IN their_PRP$ morphology_NN ,_, their_PRP$ strong_JJ adherence_NN to_TO
          plastic_NN or_CC glass_NN ,_, and_CC their_PRP$ ability_NN to_TO proliferate_VBP in_IN
          DMEM-_NNP 20_CD %_NN FCS_NNP without_IN added_JJ growth_NN factors_NNS (_( ie_NN <_NN 1_CD %_NN of_IN
          the_DT starting_VBG 2_CD ×_NN 10_CD 7_CD elutriated_JJ cells_NNS represents_VBZ 1000_CD to_TO
          10_CD 000_CD BMPCs_NNP )_) ._. Therefore_RB ,_, it_PRP is_VBZ likely_JJ that_IN 500_CD ml_NN of_IN
          normal_JJ blood_NN will_MD have_VB several_JJ thousand_CD BMPCs_NNP ._.
          Cultures_NNP were_VBD established_VBN with_IN 5_CD ×_NN 10_CD 5_CD cells_NNS from_IN the_DT
          elutriation_NN fractions_NNS and_CC proliferation_NN was_VBD measured_VBN on_IN
          days_NNS 3_CD ,_, 10_CD ,_, and_CC 17_CD ._. Nonadherent_NNP cells_NNS were_VBD removed_VBN in_IN the_DT
          first_JJ 24_CD h_NN and_CC the_DT cultures_NNS were_VBD fed_VBN twice_RB weekly_JJ ._. The_DT
          cells_NNS grew_VBD logarithmically_RB ,_, with_IN an_DT approximate_JJ doubling_NN
          time_NN of_IN 2_CD ._. 5_CD days_NNS ._. By_IN day_NN 17_CD ,_, the_DT initial_JJ 5_CD ×_NN 10_CD 5_CD cells_NNS
          multiplied_VBN to_TO 6_CD ._. 7_CD ×_NN 10_CD 7_CD (_( Table_NNP 1_LS )_) ._. The_DT culture_NN conditions_NNS
          are_VBP not_RB conducive_JJ to_TO growth_NN of_IN lymphocytes_NNS or_CC monocytes_NNS ;_:
          therefore_RB ,_, by_IN week_NN 3_CD ,_, most_JJS of_IN the_DT proliferating_VBG
          population_NN in_IN cultures_NNS were_VBD mesenchymal_NN cells_NNS (_( <_NN 20_CD %_NN
          CD_NNP 14_CD -_: staining_VBG cells_NNS ;_: data_NNS not_RB shown_VBN )_) ._.
          Cells_NNP from_IN a_DT BMPC-rich_NNP elutriation_NN fraction_NN of_IN healthy_JJ
          human_JJ blood_NN were_VBD cultured_JJ in_IN DMEM-_NNP 20_CD %_NN FCS_NNP ._. At_IN days_NNS 3_CD ,_, 5_CD ,_,
          8_CD ,_, and_CC 11_CD the_DT cultured_JJ cells_NNS were_VBD fixed_VBN ,_, stained_JJ with_IN
          anti-_NN BMPR_NNP antibodies_NNS ,_, and_CC quantified_VBN with_IN an_DT autoanalyzer_NN
          (_( described_VBD in_IN Methods_NNP )_) ._. The_DT results_NNS are_VBP presented_VBN in_IN Fig_NNP ._.
          3_LS as_IN the_DT means_NNS of_IN the_DT total_JJ number_NN of_IN cells_NNS in_IN six_CD
          individual_JJ images_NNS ._. Big_JJ cells_NNS plus_CC fibroblast-like_JJ cells_NNS
          constituted_VBD 37_CD %_NN to_TO 59_CD %_NN of_IN the_DT total_NN ._. Cells_NNP with_IN a_DT
          fibroblast-like_JJ morphology_NN varied_VBD from_IN 21_CD %_NN to_TO 34_CD %_NN of_IN the_DT
          BMPCs_NNP ._. The_DT 1_CD :_: 2_CD ratio_NN of_IN fibroblast-like_JJ to_TO big_JJ cells_NNS
          remained_VBD relatively_RB stable_JJ over_IN 11_CD days_NNS of_IN culture_NN ,_, even_RB
          as_IN the_DT total_JJ cell_NN numbers_NNS increased_VBN (_( see_VB Table_NNP 1_LS )_) ._.
        
        
          Immunohistology_NNP of_IN BMPCs_NNP
          Elutriated_NNP cells_NNS were_VBD grown_VBN on_IN sterile_JJ 12_CD -_: well_RB glass_NN
          slides_NNS (_( ICN_NNP )_) in_IN DMEM-_NNP 20_CD %_NN FCS_NNP and_CC 6_CD to_TO 12_CD days_NNS later_RB the_DT
          cells_NNS were_VBD fixed_VBN ,_, stained_JJ ,_, and_CC examined_VBN by_IN
          immunohistology_NN (_( Table_NNP 2_LS )_) ._. The_DT large_JJ cells_NNS and_CC the_DT
          fibroblast-like_JJ cells_NNS stained_JJ with_IN antibodies_NNS to_TO both_DT
          vimentin_NN and_CC collagen_NN type_NN I_PRP ._. They_PRP were_VBD also_RB identified_VBN
          by_IN antibodies_NNS to_TO one_CD or_CC the_DT other_JJ chain_NN (_( type_NN IA_NNP and_CC type_NN
          II_NNP )_) of_IN the_DT BMPR_NNP (_( Fig_NNP ._. 4_LS a_DT )_) ,_, but_CC did_VBD not_RB react_VB with_IN an_DT
          anti-type-_JJ IB-receptor-chain_NNP antibody_NN ._. Monoclonal_NNP Stro-_NNP 1_CD
          antibody_NN stained_JJ most_JJS of_IN the_DT large_JJ BMPCs_NNP and_CC a_DT few_JJ of_IN the_DT
          fibroblast-like_JJ cells_NNS ,_, while_IN anti-_NN CD_NNP 105_CD reacted_VBD with_IN both_DT
          populations_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) ._. BMPCs_NNP stained_JJ strongly_RB with_IN
          anti-_NN CD_NNP 44_CD antibody_NN ._. Conventional_JJ T-_NNP cell_NN (_( CD_NNP 3_LS )_) ,_, monocyte_NN
          (_( CD_NNP 14_CD ,_, CD_NNP 68_CD )_) ,_, and_CC B-_NNP cell_NN (_( CD_NNP 20_CD )_) antibodies_NNS stained_JJ
          neither_DT of_IN the_DT two_CD BMPC_NNP populations_NNS ,_, nor_CC did_VBD they_PRP react_VBP
          to_TO anti-_NN LCA_NNP (_( CD_NNP 45_CD )_) ,_, anti-_NN VCAM_NNP (_( CD_NNP 106_CD )_) ,_, or_CC MHC-Class_NNP II_NNP
          (_( anti-_NN DR_NNP )_) ._.
        
        
          Cell_NNP separation_NN by_IN magnetic_JJ beads_NNS to_TO analyze_VB the_DT
          contribution_NN of_IN CD_NNP 34_CD +_NN progenitors_NNS ,_, monocytes_NNS ,_, and_CC T_NN
          lymphocytes_NNS to_TO BMPC_NNP formation_NN
          BMPC-rich_NNP elutriation_NN fractions_NNS were_VBD incubated_JJ with_IN
          magnetic_JJ beads_NNS coated_VBN with_IN specific_JJ antibodies_NNS and_CC
          subsequently_RB separated_JJ into_IN adherent_NN (_( antigen-enriched_JJ )_)
          and_CC nonadherent_NN (_( antigen-depleted_JJ )_) populations_NNS ._. These_DT
          were_VBD cultured_JJ in_IN complete_JJ medium_NN in_IN six-well_JJ plates_NNS and_CC
          observed_VBD daily_JJ by_IN phase-contrast_JJ microscopy_NN ._. The_DT
          CD_NNP 34_CD -_: depleted_VBN fraction_NN always_RB developed_VBD many_JJ examples_NNS of_IN
          both_DT types_NNS of_IN mesenchymal_NN cells_NNS (_( seven_CD experiments_NNS )_) ._. The_DT
          fibroblast-like_JJ cells_NNS appeared_VBD in_IN the_DT CD_NNP 34_CD -_: depleted_VBN
          cultures_NNS at_IN the_DT same_JJ time_NN as_IN in_IN untreated_JJ controls_NNS
          (_( usually_RB day_NN 3_CD or_CC 4_LS )_) ._. There_EX were_VBD not_RB enough_RB CD_NNP 34_CD +_NN cells_NNS
          to_TO establish_VB cultures_NNS ._. A_DT representative_NN experiment_NN is_VBZ
          shown_VBN in_IN Table_NNP 3_CD ._. In_IN two_CD additional_JJ experiments_NNS ,_, the_DT
          cells_NNS from_IN the_DT elutriation_NN fraction_NN were_VBD exposed_VBN to_TO CD_NNP 34_CD
          beads_NNS and_CC the_DT negative_JJ fraction_NN was_VBD separated_JJ again_RB on_IN
          fresh_JJ CD_NNP 34_CD beads_NNS ._. There_EX was_VBD no_DT reduction_NN in_IN the_DT time_NN of_IN
          appearance_NN or_CC number_NN of_IN fibroblast-like_JJ cells_NNS ._. Thus_RB ,_,
          although_IN BMPCs_NNP were_VBD present_JJ in_IN an_DT elutriation_NN fraction_NN
          that_WDT contained_VBD CD_NNP 34_CD +_NN cells_NNS ,_, the_DT two_CD types_NNS of_IN cell_NN could_MD
          be_VB distinguished_VBN from_IN one_CD another_DT ._.
          Findings_NNP with_IN anti-_NN CD_NNP 14_CD beads_NNS were_VBD somewhat_RB different_JJ ._.
          Both_DT CD_NNP 14_CD +_NN and_CC CD_NNP 14_CD -_: eluates_NNS developed_VBD fibroblast-like_JJ
          cells_NNS in_IN culture_NN ,_, but_CC the_DT numbers_NNS were_VBD less_JJR than_IN in_IN
          unfractionated_JJ controls_NNS ._. In_IN four_CD of_IN five_CD experiments_NNS ,_, the_DT
          fibroblast-like_JJ cells_NNS in_IN the_DT CD_NNP 14_CD +_NN fraction_NN appeared_VBD
          sooner_RBR and_CC in_IN greater_JJR numbers_NNS than_IN the_DT CD_NNP 14_CD -_: fraction_NN ._. In_IN
          all_DT instances_NNS ,_, however_RB ,_, each_DT fraction_NN contained_VBD both_DT
          large_JJ ,_, round_NN cells_NNS and_CC fibroblast-like_JJ cells_NNS and_CC their_PRP$
          numbers_NNS become_VBP more_RBR equal_JJ with_IN time_NN (_( usually_RB by_IN day_NN 13_CD )_) ._.
          A_DT representative_NN experiment_NN is_VBZ shown_VBN in_IN Table_NNP 3_CD ._. When_WRB the_DT
          CD_NNP 14_CD +_NN and_CC CD_NNP 14_CD -_: populations_NNS were_VBD combined_VBN ,_, the_DT number_NN of_IN
          fibroblast-like_JJ cells_NNS and_CC their_PRP$ time_NN of_IN appearance_NN was_VBD
          the_DT same_JJ as_IN in_IN unfractionated_JJ controls_NNS ._.
          T-_NNP cell_NN depletion_NN had_VBD no_DT effect_NN on_IN the_DT number_NN ,_,
          morphology_NN ,_, or_CC time_NN of_IN appearance_NN of_IN mesenchymal_NN cells_NNS
          (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          Pluripotent_NNP BMPC-fibroblast_NNP ,_, osteoblast_NN ,_, and_CC
          adipocyte_NN formation_NN
          BMPC-rich_NNP elutriation_NN fractions_NNS cultured_JJ in_IN complete_JJ
          medium_NN supported_VBD growth_NN of_IN fibroblasts_NNS (_( spindle-shaped_JJ
          cells_NNS stained_JJ by_IN antibodies_NNS to_TO vitronectin_NN and_CC type_NN I_PRP
          collagen_NN )_) ._. When_WRB the_DT same_JJ elutriated_JJ cells_NNS were_VBD
          supplemented_JJ with_IN dexamethasone_NN ,_, ascorbic_JJ acid_NN ,_, and_CC
          β-glycerophosphate_JJ their_PRP$ morphology_NN altered_VBD ,_, and_CC they_PRP
          became_VBD uniform_NN ,_, polygonal_NN cells_NNS reminiscent_NN of_IN
          osteoblasts_NNS (_( Fig_NNP ._. 1_LS c_SYM )_) ._. By_IN 10_CD days_NNS ,_, many_JJ of_IN the_DT cells_NNS
          stained_JJ for_IN AP_NNP (_( not_RB shown_VBN )_) ._. Over_IN the_DT next_JJ 1_CD to_TO 2_CD weeks_NNS ,_, a_DT
          subpopulation_NN (_( approximately_RB 30_CD %_NN )_) of_IN large_JJ cells_NNS (_( which_WDT
          were_VBD 3_CD -_: to_TO 6_CD -_: fold_VB bigger_JJR than_IN monocytes_NNS )_) developed_VBN ._. They_PRP
          accumulated_VBN an_DT ill-defined_JJ pericellular_NN matrix_NN and_CC the_DT
          osteoblast-specific_JJ protein_NN osteocalcin_NN (_( Fig_NNP ._. 5_LS aand_NN b_SYM )_) ._.
          In_IN the_DT same_JJ supplemented_JJ cultures_NNS were_VBD sudanophilic_JJ
          adipocytes_NNS (_( Fig_NNP ._. 5_LS a_DT )_) ._. Another_DT large_JJ cell_NN present_JJ after_IN 1_CD
          week_NN in_IN the_DT supplemented_JJ cultures_NNS had_VBD multiple_JJ nuclei_NN
          (_( Fig_NNP ._. 6_CD a_DT )_) and_CC stained_JJ for_IN tartrate-resistant_JJ acid_NN
          phosphatase_NN (_( TRAP_NNP )_) and_CC the_DT vitronectin_NN receptor_NN (_( Fig_NNP ._.
          6_CD b_SYM )_) ,_, which_WDT are_VBP features_NNS of_IN osteoclasts_NNS (_( OCs_NNP )_) ._.
          OCs_NNP developed_VBD in_IN the_DT supplemented_JJ BMPC_NNP cultures_NNS
          because_IN both_DT monocytes_NNS and_CC stem_VB cells_NNS (_( and_CC /_NN or_CC
          pre-osteoblasts_JJ )_) were_VBD present_JJ together_RB in_IN the_DT elutriated_JJ
          cells_NNS ._.
        
        
          Alkaline_NNP phosphatase_NN production_NN
          BMPC-rich_NNP elutriation_NN fractions_NNS from_IN four_CD separate_JJ
          blood_NN packs_NNS were_VBD cultured_JJ in_IN complete_JJ medium_NN with_IN varying_VBG
          concentrations_NNS of_IN BMP_NN 2_CD for_IN 5_CD days_NNS and_CC AP_NNP in_IN the_DT
          supernatants_NNS was_VBD measured_VBN (_( Fig_NNP ._. 7_CD )_) ._. The_DT lowest_JJS
          concentration_NN of_IN BMP_NN 2_CD (_( 1_CD ng_NN /_NN ml_NN )_) caused_VBD a_DT significant_JJ
          increase_NN in_IN AP_NNP activity_NN (_( 
          P_NN =_SYM 0_CD ._. 004_CD )_) ._. This_DT represents_VBZ an_DT
          increased_VBN AP_NNP production_NN per_IN cell_NN ,_, because_IN BMP_NN 2_CD had_VBD no_DT
          effect_NN on_IN BMPC_NNP proliferation_NN over_IN 5_CD days_NNS (_( data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Stromal-cell-derived_NNP factor_NN 1_CD
          SDF-_NNP 1_CD is_VBZ a_DT potent_JJ CXCα_NNP chemokine_NN produced_VBN by_IN
          bone-marrow_NN spindle-shaped_JJ stromal_NN cells_NNS and_CC other_JJ cells_NNS
          of_IN mesenchymal_NN origin_NN ,_, but_CC not_RB blood_NN leukocytes_NNS [_NN 12_CD ,_,
          13_CD ]_NN ._. RT-PCR_NNP analysis_NN for_IN SDF-_NNP 1_CD mRNA_NN expression_NN in_IN two_CD
          cDNA_NN samples_NNS of_IN cultured_JJ BMPCs_NNP (_( lanes_NNS 2_CD and_CC 3_LS )_) and_CC in_IN a_DT
          cDNA_NN from_IN RA_NNP synoviocytes_NNS (_( lane_NN 4_LS )_) are_VBP shown_VBN in_IN Fig_NNP ._.
          8_CD ._.
          Each_DT sample_NN displayed_VBD an_DT amplification_NN of_IN a_DT PCR_NNP
          fragment_NN of_IN the_DT expected_VBN size_NN for_IN SDF-_NNP 1_CD (_( 296_CD bp_NN )_) and_CC was_VBD
          similar_JJ to_TO the_DT positive_JJ control_NN (_( lane_NN 5_LS )_) ,_, a_DT sequenced_JJ
          plasmid_NN containing_VBG human_JJ SDF-_NNP 1_CD β_NN cDNA_NN ._.
        
      
      
        Discussion_NNP
        The_DT abilities_NNS to_TO self-replicate_JJ and_CC to_TO give_VB rise_NN to_TO
        daughter_NN cells_NNS that_WDT undergo_VBP an_DT irreversible_JJ terminal_NN
        differentiation_NN are_VBP features_NNS of_IN stem_NN cells_NNS [_NN 14_CD ,_, 15_CD ]_NN ._. The_DT
        best-characterized_JJ are_VBP HSCs_NNP and_CC their_PRP$ progeny_NN ._. Friedenstein_NNP
        
        et_CC al_NN proposed_VBD a_DT similar_JJ scheme_NN for_IN
        mesenchymal_NN cells_NNS and_CC showed_VBD that_DT bone_NN marrow_NN contained_VBD
        primitive_JJ cells_NNS that_WDT could_MD generate_VB progenitors_NNS committed_VBN
        to_TO one_CD or_CC another_DT mesenchymal_NN line_NN [_NN 2_CD ]_NN ._. Such_JJ cells_NNS are_VBP
        called_VBN MSCs_NNP [_NN 1_CD ]_NN ._. Conditions_NNP that_IN direct_JJ marrow_NN MSCs_NNP along_IN
        myogenic_JJ [_NN 16_CD ]_NN ,_, adipogenic_JJ [_NN 17_CD ,_, 18_CD ]_NN ,_, osteogenic_JJ [_NN 18_CD ,_, 19_CD ,_,
        20_CD ]_NN ,_, chondrogenic_JJ [_NN 19_CD ,_, 21_CD ]_NN ,_, and_CC stromal_NN pathways_NNS [_NN 22_CD ]_NN
        have_VBP been_VBN defined_VBN ._. For_IN instance_NN ,_, exposure_NN of_IN
        fibroblast-like_JJ marrow_NN MSCs_NNP 
        in_IN vitro_NN to_TO optimal_NN concentrations_NNS of_IN
        dexamethasone_NN ,_, ascorbic_JJ acid_NN and_CC β-glycerophosphate_JJ induces_VBZ
        a_DT cuboidal_NN morphology_NN ,_, upregulates_NNS AP_NNP and_CC osteocalcin_NN
        expression_NN ,_, and_CC a_DT mineralized_JJ (_( hydroxyapatite_NN )_) matrix_NN [_NN
        20_CD ]_NN ._.
        Lineage_NNP differentiation_NN signals_NNS can_MD be_VB subtle_JJ ._.
        Dexamethasone_NNP at_IN 10_CD -_: 9_CD mol_NN /_NN l_NN supports_VBZ adipocyte_NN
        differentiation_NN ,_, whereas_IN osteogenesis_NNS is_VBZ favored_VBN at_IN 10_CD
        -_: 7_CD mol_NN /_NN l_NN [_NN 19_CD ]_NN ._. Human_JJ marrow_NN MSCs_NNP obtained_VBN by_IN Ficoll_NNP density_NN
        gradient_NN fractionation_NN (_( 1_CD ._. 078_CD g_SYM /_NN ml_NN )_) and_CC cultured_JJ in_IN 25_CD %_NN
        serum_NN (_( half_JJ horse_NN and_CC half_NN fetal_JJ calf_NN )_) supplemented_JJ with_IN
        hydrocortisone_NN (_( 1_CD μmol_NN )_) gives_VBZ rise_NN to_TO a_DT heterogeneous_JJ
        population_NN ,_, in_IN which_WDT fibroblast-like_JJ cells_NNS do_VBP not_RB
        predominate_NN [_NN 22_CD ]_NN ._. Separation_NNP of_IN the_DT same_JJ population_NN of_IN
        marrow_NN MSCs_NNP on_IN a_DT Percoll_NNP density_NN gradient_NN (_( 1_CD ._. 090_CD g_SYM /_NN ml_NN )_) and_CC
        culture_NN in_IN carefully_RB selected_VBN 10_CD %_NN FCS_NNP resulted_VBD in_IN a_DT
        homogeneous_JJ population_NN of_IN spindle-shaped_JJ fibroblast_NN cells_NNS ._.
        The_DT higher-density_JJ Ficoll_NNP may_MD isolate_VB cells_NNS that_WDT sediment_NN
        through_IN the_DT Percoll_NNP solution_NN used_VBN for_IN the_DT marrow_NN MSC_NNP
        isolation_NN ._. Elutriation_NNP ,_, as_IN used_VBN in_IN this_DT investigation_NN ,_,
        probably_RB selects_VBZ a_DT somewhat_RB different_JJ population_NN ._.
        The_DT CD_NNP 34_CD status_NN of_IN mesenchymal_NN cells_NNS is_VBZ disputed_VBN [_NN 7_CD ,_,
        8_CD ]_NN ._. A_DT minority_NN of_IN adult_NN marrow_NN cells_NNS express_VBP CD_NNP 34_CD ._. The_DT
        antigen_NN is_VBZ present_JJ on_IN pluripotent_NN HSCs_NNP ,_, and_CC all_DT unipotent_NN
        myeloid_NN and_CC erythroid-colony-forming_JJ cells_NNS [_NN 23_CD ]_NN ,_, but_CC CD_NNP 34_CD
        is_VBZ also_RB recognized_VBN on_IN vascular_NN endothelial_NN cells_NNS ,_,
        basement-membrane_JJ structures_NNS ,_, and_CC dendritic_JJ and_CC
        perifollicular_NN cells_NNS in_IN human_JJ skin_NN [_NN 24_CD ,_, 25_CD ]_NN ._. Simmons_NNP and_CC
        Torok-_NNP Storb_NNP separated_JJ human_JJ marrow_NN cells_NNS on_IN the_DT basis_NN of_IN
        their_PRP$ CD_NNP 34_CD expression_NN [_NN 26_CD ]_NN ._. More_JJR than_IN 95_CD %_NN of_IN the_DT
        detectable_JJ colony_NN forming_VBG unit_NN fibroblasts_NNS were_VBD recovered_VBN
        in_IN the_DT adherent_NN CD_NNP 34_CD +_NN population_NN ,_, but_CC their_PRP$ CD_NNP 34_CD density_NN
        was_VBD much_RB less_JJR than_IN on_IN CD_NNP 34_CD highHSCs_NNS ._. Furthermore_RB ,_, only_RB 5_CD %_NN
        of_IN the_DT CD_NNP 34_CD +_NN marrow_NN cells_NNS reacted_VBD with_IN the_DT monoclonal_NN
        antibody_NN Stro-_NNP 1_CD ,_, which_WDT identifies_VBZ marrow_NN MSCs_NNP [_NN 6_CD ]_NN ._. All_DT
        these_DT studies_NNS were_VBD done_VBN on_IN marrow_NN MSCs_NNP before_IN culture_NN ,_,
        because_IN after_IN culture_NN 
        in_IN vitro_NN ,_, the_DT same_JJ stromal_NN cells_NNS no_RB
        longer_RB react_VB with_IN anti-_NN CD_NNP 34_CD antibodies_NNS [_NN 26_CD ]_NN ._. Likewise_RB ,_,
        although_IN CD_NNP 34_CD +_NN cells_NNS are_VBP identified_VBN in_IN tissue_NN sections_NNS of_IN
        human_JJ umbilical_JJ vein_NN endothelial_NN cells_NNS ,_, they_PRP are_VBP not_RB found_VBN 
        in_IN vitro_NN [_NN 27_CD ]_NN ._. These_DT and_CC other_JJ
        reports_NNS suggest_VBP the_DT CD_NNP 34_CD glycoprotein_NN is_VBZ either_CC
        down-regulated_JJ or_CC modified_VBN 
        in_IN vitro_NN to_TO a_DT form_NN that_WDT is_VBZ not_RB
        reactive_JJ with_IN the_DT usual_JJ anti-_NN CD_NNP 34_CD antibodies_NNS [_NN 23_CD ]_NN ._.
        Therefore_RB ,_, the_DT failure_NN of_IN Fernandez_NNP 
        et_CC al_NN to_TO demonstrate_VB CD_NNP 34_CD on_IN
        circulating_VBG stromal_NN cells_NNS mobilized_VBN by_IN growth_NN factors_NNS was_VBD
        probably_RB because_IN the_DT cells_NNS had_VBD been_VBN in_IN culture_NN for_IN 10_CD days_NNS
        [_NN 7_CD ]_NN ._. Similarly_RB ,_, the_DT inability_NN of_IN Majumdar_NNP 
        et_CC al_NN to_TO demonstrate_VB CD_NNP 34_CD staining_VBG
        was_VBD on_IN first-passage_JJ marrow_NN MSCs_NNP [_NN 22_CD ]_NN ._. 
        In_IN vitro_NN culture_NN conditions_NNS ,_, however_RB ,_,
        cannot_NN explain_VB our_PRP$ failure_NN to_TO eliminate_VB BMPCs_NNP in_IN fresh_JJ
        elutriation_NN fractions_NNS with_IN anti-_NN CD_NNP 34_CD -_: coated_JJ magnetic_JJ beads_NNS ,_,
        a_DT technique_NN widely_RB used_VBD to_TO harvest_NN CD_NNP 34_CD +_NN HSCs_NNP from_IN
        growth-factor-mobilized_JJ human_JJ blood_NN ._. The_DT absorptions_NNS were_VBD
        performed_VBN on_IN fresh_JJ BMPC-rich_NNP elutriation_NN fractions_NNS ._.
        Therefore_RB ,_, BMPCs_NNP either_CC lack_NN CD_NNP 34_CD or_CC have_VBP only_RB a_DT very_RB low_JJ
        density_NN of_IN this_DT glycoprotein_NN ._.
        The_DT CD_NNP 34_CD +_NN cells_NNS called_VBN fibrocytes_NNS ,_, which_WDT are_VBP present_JJ in_IN
        monocyte_NN fractions_NNS of_IN human_JJ blood_NN and_CC develop_VB a_DT fibroblast_NN
        morphology_NN when_WRB grown_VBN on_IN fibronectin_NN ,_, have_VBP features_NNS
        identical_JJ to_TO those_DT of_IN circulating_VBG vascular_NN endothelial_NN cell_NN
        progenitors_NNS [_NN 28_CD ]_NN and_CC are_VBP probably_RB not_RB BMPCs_NNP ._.
        Bone_NNP morphogenetic_JJ proteins_NNS (_( BMPs_NNP )_) were_VBD originally_RB
        identified_VBN as_IN proteins_NNS that_WDT induced_VBD bone_NN formation_NN at_IN
        extraskeletal_NN sites_NNS [_NN 29_CD ]_NN ._. Currently_RB ,_, there_EX are_VBP 20_CD or_CC more_RBR
        known_JJ BMPs_NNP ,_, all_DT members_NNS of_IN a_DT larger_JJR TGF-β_NNP superfamily_RB ._. BMPs_NNP
        are_VBP involved_VBN in_IN morphogenesis_NNS and_CC embryogenesis_NNS ,_,
        influencing_VBG bone_NN ,_, cartilage_NN ,_, and_CC skeletal_NN formation_NN [_NN 29_CD ,_,
        30_CD ,_, 31_CD ,_, 32_CD ]_NN ._. Much_JJ of_IN this_DT information_NN comes_VBZ from_IN animal_NN
        cells_NNS and_CC embryos_NNS ,_, but_CC the_DT addition_NN of_IN BMP_NN 2_CD to_TO cultured_JJ
        postnatal_NN human_JJ bone_NN marrow_NN `_`` preosteoblastic_JJ '_'' cells_NNS in_IN the_DT
        presence_NN of_IN β-glycerophosphate_JJ and_CC ascorbic_JJ acid_NN increases_VBZ
        the_DT gene_NN message_NN and_CC protein_NN production_NN of_IN AP_NNP ,_, osteopontin_NN ,_,
        bone_NN sialoprotein_NN ,_, osteocalcin_NN ,_, and_CC α-_NN 1_CD collagen_NN [_NN 33_CD ]_NN ._.
        BMPCs_NNP develop_VB into_IN osteocalcin-producing_JJ cells_NNS (_( Fig_NNP ._. 5_LS a_DT )_)
        and_CC make_VB increased_VBN amounts_NNS of_IN AP_NNP in_IN response_NN to_TO BMP_NN 2_CD (_( Fig_NNP ._.
        7_CD )_) ._. This_DT cannot_NN be_VB explained_VBN by_IN proliferation_NN ,_, because_IN BMP_NN 2_CD
        reduces_VBZ the_DT number_NN of_IN marrow_NN MSCs_NNP in_IN either_DT serum_NN or_CC
        serum-free_JJ conditions_NNS [_NN 33_CD ]_NN ._.
        BMPRs_NNP belong_VBP to_TO the_DT TGF-β_NNP receptor_NN family_NN of_IN
        serine_NN /_NN threonine_NN kinases_NNS [_NN 34_CD ]_NN ._. Both_DT type_NN I_PRP and_CC type_NN II_NNP
        BMPRs_NNP bind_NN their_PRP$ respective_JJ ligands_NNS ,_, but_CC heterodimerization_NN
        is_VBZ required_VBN for_IN a_DT signal_NN to_TO be_VB transduced_JJ [_NN 34_CD ,_, 35_CD ]_NN ._. For_IN
        instance_NN ,_, coexpression_NN of_IN type_NN II_NNP BMPR_NNP with_IN either_DT IA_NNP or_CC IB_NNP
        BMPR_NNP increases_NNS ligand-binding_JJ affinity_NN and_CC dramatically_RB
        enhances_VBZ biologic_JJ activity_NN [_NN 11_CD ]_NN ._. Human_JJ marrow_NN MSCs_NNP express_VB
        BMP_NN 2_CD /_NN 4_CD type_NN I_PRP and_CC II_NNP receptors_NNS as_IN shown_VBN in_IN studies_NNS
        employing_VBG BMP_NN 2_CD as_IN ligand_NN in_IN the_DT presence_NN or_CC absence_NN of_IN a_DT
        100_CD -_: fold_VB excess_NN of_IN a_DT competitor_NN [_NN 33_CD ]_NN ._. BMP_NN structure_NN is_VBZ
        conserved_JJ across_IN species_NNS ,_, and_CC antibodies_NNS to_TO type_NN I_PRP and_CC
        typeII_NN receptors_NNS react_VBP equally_RB well_RB with_IN murine_NN and_CC human_JJ
        mesenchymal_NN cells_NNS ,_, but_CC not_RB with_IN hematopoietic_JJ cells_NNS [_NN 34_CD ]_NN ._.
        This_DT is_VBZ consistent_JJ with_IN our_PRP$ findings_NNS that_WDT polyclonal_NN
        antibody_NN to_TO BMPRs_NNP can_MD be_VB used_VBN to_TO identify_VB BMPCs_NNP and_CC
        constitutes_VBZ strong_JJ evidence_NN that_IN the_DT circulating_VBG cells_NNS
        described_VBD in_IN this_DT report_NN are_VBP mesenchymal_NN precursors_NNS ._.
        BMPCs_NNP stain_VB with_IN the_DT Stro-_NNP 1_CD monoclonal_NN antibody_NN made_VBN
        against_IN human_JJ bone-marrow_NN stromal_NN cells_NNS [_NN 6_CD ]_NN ._. Stro-_NNP 1_CD +_NN cells_NNS
        cultured_JJ in_IN an_DT osteogenic_JJ medium_NN exhibit_NN three_CD markers_NNS of_IN
        differentiated_JJ bone_NN :_: AP_NNP ;_: 1_CD ,_, 25_CD -_: dihydroxyvitamin-_NN D_NNP 
        3_CD -_: dependent_JJ induction_NN of_IN osteocalcin_NN ;_:
        and_CC a_DT mineralized_JJ matrix_NN (_( hydroxyapatite_NN )_) [_NN 36_CD ,_, 37_CD ]_NN ._. Stro-_NNP 1_CD
        is_VBZ expressed_VBN by_IN BMPCs_NNP ,_, but_CC the_DT antibody_NN also_RB stains_NNS
        pericytes_NNS ,_, cells_NNS that_WDT surround_VBP small-vessel_JJ endothelium_NN ._.
        Pericytes_NNP ,_, which_WDT are_VBP of_IN mesodermal_NN origin_NN ,_, can_MD also_RB
        differentiate_VB into_IN a_DT variety_NN of_IN cell_NN types_NNS ,_, including_VBG
        osteoblasts_NNS and_CC adipocytes_NNS (_( reviewed_VBN in_IN [_NN 38_CD ]_NN )_) ._. The_DT
        reactivity_NN of_IN pericytes_NNS with_IN BMPR_NNP antibodies_NNS is_VBZ not_RB known_VBN ,_,
        but_CC we_PRP have_VBP used_VBN BMPR_NNP antibodies_NNS to_TO analyze_VB mesenchymal_NN
        cells_NNS in_IN synovial_NN tissues_NNS ._. The_DT antibodies_NNS identify_VBP large_JJ
        cells_NNS in_IN the_DT inflamed_JJ joint_JJ lining_NN ,_, but_CC they_PRP do_VBP not_RB stain_VB
        blood_NN vessels_NNS of_IN either_DT normal_JJ or_CC inflamed_JJ synovium_NN
        (_( Marinova-_NNP Mutafchieva_NNP ,_, personal_JJ communication_NN )_) ._.
        SH-_NNP 2_CD ,_, a_DT proprietary_JJ antibody_NN developed_VBN against_IN isolated_VBN
        bone_NN marrow_NN MSCs_NNP [_NN 1_CD ,_, 3_CD ]_NN ,_, was_VBD not_RB available_JJ when_WRB these_DT
        studies_NNS were_VBD performed_VBN ._. When_WRB SH-_NNP 2_CD was_VBD identified_VBN as_IN
        endoglin_NN (_( CD_NNP 105_CD )_) [_NN 4_CD ]_NN ,_, the_DT cells_NNS in_IN a_DT BMPC-enriched_NNP
        elutriation_NN fraction_NN of_IN blood_NN were_VBD examined_VBN with_IN an_DT
        anti-_NN CD_NNP 105_CD monoclonal_NN antibody_NN ._. The_DT strong_JJ cytoplasmic_JJ
        staining_VBG of_IN the_DT large_JJ blood_NN mesenchymal_NN cells_NNS (_( Fig_NNP ._. 4_LS b_SYM )_) is_VBZ
        more_JJR evidence_NN of_IN the_DT great_JJ similarity_NN of_IN marrow_NN MSCs_NNP and_CC
        circulating_VBG BMPCs_NNP ._.
        Progenitor_NNP and_CC precursor_NN B_NNP cells_NNS require_VBP close_JJ contact_NN
        with_IN marrow_NN MSCs_NNP for_IN growth_NN and_CC maturation_NN ._. Mouse_NNP marrow_NN
        MSCs_NNP contain_VB the_DT gene_NN for_IN a_DT protein_NN (_( termed_VBD either_CC
        stromal-cell-derived_JJ factor_NN 1_CD (_( SDF-_NNP 1_LS )_) or_CC
        pre-_NN B-_NNP cell-growth-stimulating_JJ factor_NN (_( PBSF_NNP )_) [_NN 12_CD ,_, 13_CD ]_NN ._.
        SDF-_NNP 1_CD is_VBZ a_DT powerful_JJ CXC_NNP chemokine_NN that_WDT recruits_VBZ circulating_VBG
        lymphocytes_NNS ,_, monocytes_NNS ,_, and_CC CD_NNP 34_CD +_NN hematopoietic_JJ
        progenitors_NNS ,_, but_CC not_RB neutrophils_NNS [_NN 39_CD ,_, 40_CD ]_NN ._. PBSF_NNP is_VBZ
        responsible_JJ for_IN converting_VBG `_`` early_JJ '_'' B_NNP cells_NNS into_IN
        immunoglobulin-producing_JJ cells_NNS [_NN 41_CD ]_NN ._. SDF-_NNP 1_CD mRNA_NN is_VBZ
        constitutively_RB expressed_VBN in_IN many_JJ tissues_NNS ,_, unlike_IN other_JJ
        chemokines_NNS ,_, which_WDT are_VBP only_RB induced_VBN [_NN 41_CD ,_, 42_CD ]_NN ._. SDF-_NNP 1_CD is_VBZ
        expressed_VBN in_IN marrow_NN MSCs_NNP ,_, dermal_NN fibroblasts_NNS ,_, and_CC synovial_NN
        fibroblasts_NNS ,_, but_CC not_RB HSCs_NNP ._. The_DT demonstration_NN of_IN
        constitutive_JJ expression_NN of_IN SDF-_NNP 1_CD mRNA_NN in_IN cultured_JJ BMPCs_NNP
        (_( Fig_NNP ._. 8_CD )_) and_CC as_IN protein_NN in_IN supernatants_NNS from_IN cultured_JJ BMPCs_NNP
        (_( data_NNS not_RB presented_VBN )_) is_VBZ additional_JJ evidence_NN that_IN BMPCs_NNP are_VBP
        of_IN mesenchymal_NN lineage_NN ._.
        Human_NNP OCs_NNP arise_VB from_IN HSCs_NNP in_IN close_JJ proximity_NN to_TO stromal_NN
        cells_NNS or_CC from_IN blood_NN monocytes_NNS ._. The_DT OC_NNP is_VBZ a_DT TRAP-positive_NNP ,_,
        large_JJ ,_, multinucleated_JJ cell_NN with_IN receptors_NNS for_IN calcitonin_NN
        and_CC vitronectin_NN (_( αvβ_NN 3_LS )_) (_( Fig_NNP ._. 5_LS a_DT )_) and_CC the_DT capacity_NN to_TO form_VB
        resorption_NN lacunae_NN in_IN bone_NN slices_NNS [_NN 43_CD ]_NN ._. Osteoblast_NNP
        production_NN and_CC OC_NNP production_NN are_VBP tightly_RB linked_VBN and_CC
        regulated_VBN ._. Osteoblasts_NNP facilitate_VB OC_NNP formation_NN by_IN providing_VBG
        physical_JJ support_NN and_CC critical_JJ soluble_JJ factors_NNS [_NN 43_CD ]_NN ._. Our_PRP$
        observation_NN of_IN spontaneous_JJ formation_NN of_IN cells_NNS with_IN the_DT
        morphology_NN and_CC phenotype_NN of_IN OCs_NNP in_IN monocyte-rich_JJ (_( 65_CD %_NN )_)
        elutriation_NN fractions_NNS is_VBZ best_JJS explained_VBN by_IN the_DT simultaneous_JJ
        presence_NN of_IN BMPCs_NNP in_IN the_DT same_JJ fractions_NNS ._.
        More_JJR than_IN 100_CD normal_JJ individuals_NNS had_VBD CD_NNP 34_CD -_: mononuclear_NN
        cells_NNS in_IN a_DT fraction_NN of_IN elutriated_JJ blood_NN cells_NNS that_WDT
        fulfilled_VBD criteria_NNS for_IN mesenchymal_NN precursors_NNS or_CC stem_VB
        cells_NNS ._. They_PRP proliferated_VBN rapidly_RB in_IN culture_NN ,_, had_VBD an_DT
        adherent_NN ,_, spread_NN morphology_NN ,_, displayed_VBN cytoskeletal_NN ,_,
        cytoplasmic_JJ ,_, and_CC surface_NN markers_NNS of_IN mesenchymal_NN precursors_NNS ,_,
        and_CC had_VBD a_DT capacity_NN for_IN differentiation_NN into_IN fibroblast_NN ,_,
        osteoblast_NN ,_, and_CC adipocyte_NN lineages_NNS ._. Thus_RB ,_, autologous_JJ blood_NN
        could_MD be_VB an_DT important_JJ source_NN of_IN cells_NNS for_IN tissue_NN
        engineering_NN and_CC gene_NN therapy_NN [_NN 44_CD ,_, 45_CD ,_, 46_CD ]_NN ._. In_IN addition_NN ,_,
        the_DT finding_NN of_IN similar_JJ cells_NNS in_IN the_DT inflammatory_JJ joint_JJ
        fluids_NNS and_CC synovial_NN tissues_NNS of_IN patients_NNS with_IN RA_NNP suggests_VBZ
        they_PRP may_MD play_VB a_DT role_NN in_IN the_DT pathogenesis_NNS of_IN this_DT disease_NN [_NN
        47_CD ]_NN ._.
      
    
  
